Advancements in percutaneous coronary intervention (PCI) have led to its widespread application across a variety of clinical settings. During the same period, cardiovascular clinical trials have become increasingly globalized. 1 However, because patients with coronary artery disease (CAD) are heterogeneous, differences in patient baseline characteristics may affect the outcomes of PCI. [2] [3] [4] [5] Recent epidemiological studies have reported significant differences between continents in the prevalence of cardiovascular risk factors. For example, studies have demonstrated the lowest prevalence of type 2 diabetes mellitus (DM) 6, 7 and highest prevalence of hypertension (HTN) in Europe. 8 In contrast, Asia has the lowest prevalence of hyperlipidemia (HL) and highest prevalence of smoking among men. 9, 10 In addition, the worldwide prevalence of DM has been trending upward, whereas levels of HTN and HL have stayed consistent or have slightly decreased in North America and Europe. [11] [12] [13] [14] [15] [16] [17] [18] Furthermore, smoking has declined in every continent except Asia. 10, 11, 15, 18 Although variations in the prevalence and trends of cardiovascular risk factors in the general population are well documented in the literature, 19, 20 differences in patient characteristics within PCI clinical trials between continents have not been as well studied. We hypothesized that the prevalence of CAD risk factors among patients recruited in contemporary PCI clinical trials would vary between continents.
This systematic review aims to describe the regional differences in baseline characteristics and the traditional risk factors, such as DM, HL, HTN, and smoking, between patients enrolled in PCI trials from North America, Europe, and Asia that were published between 1990 and 2015.
Methods

Search strategy and selection criteria
This systematic review follows a strict protocol based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. 21 We searched PubMed for literature that investigated PCI procedures or compared PCI with other interventions in CAD patients. Percutaneous coronary intervention procedures were restricted to coronary stenting and angioplasty. We conducted a systematic search using various combinations of keywords such as "stent," "angioplasty," "myocardial infarction," "CAD," "cardiac catheterization," and "PCI." Studies were limited to the following pathologies: acute myocardial infarction, acute coronary syndrome, CAD, and coronary restenosis. Full-text versions of the identified studies were subsequently downloaded and analyzed. Studies written in English or with English translations were considered for inclusion; no other languages were allowed. Inclusion criteria for studies were randomized and observational PCI trials studies with n ≥ 100. Multicenter studies were only included when we could ascertain that only centers from the same continent were studied. We excluded trials that ended prior to 1990; were multicontinent or were geographically outside North America, Europe, and Asia; or observed a specific subgroup of CAD patients (eg, elderly and diabetic patients). We also excluded studies that were only available in abstract format or lacked retrievable electronic copies. We excluded trials from other regions of the world (eg, Australia and Central and South America) due to an overall low number of published trials.
Data extraction
Three investigators (L.H., E.L., and M.V.) first judged the eligibility of every study by full-text review. Information about study design, geographic location of trial centers, sample size, and patient baseline characteristics was extracted and entered into a data sheet using a standardized protocol. The baseline characteristics-age, sex, prevalence of smoking, HL, HTN, DM, and body mass index (BMI)-were recorded whenever the data were provided. Discrepancies were resolved by consensus between the study investigators.
Outcomes
The 4 primary outcomes for this analysis were percentage of patients included in the trials with: (1) HTN, (2) DM, (3) HL, and (4) smoking. Secondary outcomes included average patient age, BMI, and proportion of male participants. Outcomes were further segmented according to the publication date and by continent (North America, Europe, and Asia).
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Statistical analyses
The unadjusted proportions of HTN, DM, HL, smoking, and male patients were calculated for each continent by summing the number of participants with each outcome and dividing by the total number of trial participants within each geographic area. To adjust the data for inherent variation between the selected studies and for other covariables, we assessed heterogeneity using Cochran Q statistics and I 2 statistics. Because significant heterogeneity was consistently present (I 2 N 50% or Cochran Q b 0.1), a random-effects meta-analysis with logit transformation was used to estimate and compare the overall proportion of each outcome by continent (North America, Europe, and Asia). In addition, a linear meta-regression model was used to study the temporal trends in these adjusted proportions of participants with HTN, DM, HL, and smoking. Linear regression models were also used to test the correlation between patient's sex and mean age with the publication year. Lastly, a mixed-effects meta-regression model was used to compare outcome proportions between continents while controlling for moderators such as age, BMI, publication year, and sex. Statistical significance was defined as P b .05. Extracted data were pooled using the "metafor" package for R software. 22 
Results
From an initial screen of 11,282 studies, we included 701 clinical trials published between 1990 and 2015 in our systematic review (Supplemental Tables I-III) . A total of 5548 distinct articles were excluded after first removing 5,033 duplicate articles. The primary reasons for exclusion were (1) lack of relevance to CAD and/or PCI (3,309 articles), (2) substudies of an already included patient population (758 articles), or (3) specific patient subsets such as the elderly or diabetic patients (673 articles; Figure 1 (Table I) . Most studies were collected from the United States, Germany, France, and South Korea (Supplemental Table IV ).
Variation in patient characteristics by continent (unadjusted data)
Nonmodifiable CAD risk factors such as age, sex, race, and height of PCI clinical trial participants were analyzed by geographic region. We found that studies conducted in Europe recruited slightly older patients (average age of 63.3 years compared with 62.8 years in Asia and 62.4 in North America) and the greatest proportion of male patients (6.6 percentage points more than in North America). Race was initially considered in this analysis, but was eventually removed as only a minimal number of studies reported the statistic (Table I) .
Modifiable CAD risk factors that were examined included HTN, DM, HL, smoking, and BMI. North American studies enrolled the highest proportion of HL and HTN patients, with more than 20 percentage points more HTN and HL patients than Asian trials. North American trial participants also had the highest average BMI (4.2 points greater than the average Asian BMI). On the other hand, Asia had a slightly higher rate of smoking and diabetic patients. The unadjusted averages and proportions of nonmodifiable and modifiable baseline characteristics by continent are summarized in Table I .
Variation in patient characteristics by continent (adjusted for heterogeneity, meta-regression with random-effects model)
As the studies included in this analysis displayed substantial heterogeneity across all baseline characteristics (I 2 N 98%), we further analyzed the data using a meta-regression with random-effects model. When controlled for study heterogeneity with this model, differences in baseline characteristics between continents persisted (Table II) .
Similar to the unadjusted data, Europe recruited the highest proportion of male participants, with 5.15 percentage points more male participants than in North American clinical trials (P b .0001). Again, we found that North American trials included the greatest percentage of HTN and HL patients, whereas Asia led all continents in the proportion of smoking ( Figure 2 ). The variations in the proportions of male, HTN, DM, HL, and smoking patients between continents were statistically significant and are detailed in Table II . Trends between continents (data adjusted with the random-effects model)
From 1990 to 2014, the rates of HTN (P b .0001, all continents) and DM (Asia, P b .002; Europe and North America, both P b .0001) trended upward, whereas smoking rates trended downward in North America (P b .009), Europe (P b .0002), and Asia (P b .0001). An increase in HL rates over time was observed only in Europe (P = .001) and North America (P b .0001), whereas no change was observed in Asia (P = .12). Conversely, the percentage of male study participants decreased slightly over time in Asia (P = .04), but no significant trend was observed in North America (P = .40) or Europe (P = .58). It is important to emphasize that almost all baseline characteristics we studied except for sex had statistically significant trends, and although the observed changes from year to year were small (eg, |β| b 0.02 for each continental baseline characteristic, suggesting a b2% change per year), this resulted in a large cumulative change during a 20-year period (Figure 3) .
During the same period, patient age increased in Europe (β = 0.380, P = .0001) and North America (β = 0.141, P = .0004) but not Asia (P = .39; Figure 4 ).
Effect of other moderators on cardiovascular risk factors (meta-regression with mixed-effects model)
The effect of continent, BMI, age, sex, and paper publication date on the prevalence of modifiable cardiovascular risk factors (i.e., HTN, HL, DM, and smoking) were also analyzed using the mixed-effects logistic regression model, which is presented in Table III. The magnitude of the correlation is represented by the coefficient (β), whereas statistical significance is determined by the P value.
In the mixed-effects logistic regression model, patient age and BMI were found to be significantly positively correlated with the proportion of HTN, HL, and DM patients, suggesting that older and larger patients tended to have more cardiovascular risk factors. In contrast, patient age and BMI were negatively correlated with smoking. When controlling for other moderators, publication year was not significantly associated with any patient baseline characteristic (Table III) .
Europe and North America, when compared against Asia, were significantly negatively correlated with HTN and DM; that is, these 2 continents recruited lower proportions of HTN and DM patients than did Asia. While North America seems to be positively correlated with HL, this effect was not statistically significant (β = 0.120, P = .800). Finally, Europe was correlated with a higher proportion of smoking (β = 0.477, P = .026; Table III) .
Analysis of the effect from other potential moderators on the patient characteristics of clinical trial populations was limited by data availability. For example, only 18.5% of North American, 0.3% of European, and 0.0% of Asian trials reported patient race (Table I) .
Discussion
In this global meta-analysis of CAD risk factors in PCI clinical trials, we have shown that patients enrolled in North American, European, and Asian PCI clinical trials have significant differences in baseline patient 
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Differences in cardiovascular risk factors between continents. Data were calculated using the random-effects model and tested for subgroup differences. Percentage with Hypertension (%) characteristics. In addition, we observed significant differences in the proportion of women enrolled across continents. Based on these findings, the generalizability and applicability of various PCI trials may be associated with significant challenges because these clinical trials may not be directly comparable. Although the worldwide difference in prevalence of cardiovascular risk factors (notably HTN, HL, DM, and smoking) has been well described in the cardiology literature, 23 little has been published on the variations of these risk factors between continents within CAD patients enrolled in PCI trials.
Our findings have potential implications on the recruitment strategy and data analysis of future PCI trials. First, the effect of an intervention may be influenced by the clinical profile of a particular region. Currently, multicontinent PCI trials may not fully control for the percentage of patients recruited from various regions. For example, the Synergy between PCI with TAXUS drug-eluting stent and Cardiac Surgery (SYNTAX) clinical trial demonstrated that major continental differences existed between patients within the same trial, with American patients having an overall higher-risk profile than European patients. These enrollment differences occurred despite a considerable effort to recruit a standardized patient population. 24 Second, publications from the same continent but different periods may not be fully comparable due to region-specific temporal variations in the prevalence of risk factors. Consequently, future meta-analyses and systematic reviews should be especially aware of trial dates and contemporary health trends when comparing clinical trials to minimize potential confounding variables.
There are several possible explanations and implications for the differences we observed.
Patient nonparticipation in clinical trials may skew data from the studied population from that of the general population. It is likely that reasons for patient nonparticipation may vary between continents. Several factors for nonparticipation in clinical trials have been proposed, including insurance status, socioeconomic society homogeneity, and differences in health care systems. It seems, however, that nonparticipation in clinical trials is more correlated with trial-related considerations than with patient-related issues. 25 Therefore, regional discrepancies in clinical trial inclusion and exclusion criteria likely have contributed to these observed differences. 26 The implications of trial nonparticipation are important because trials have reported differences in outcomes between eligible and enrolled patients. 27 Similarly, race and perceived harm have been proposed as barriers to participation in randomized controlled trials. 28 Insurance coverage has implications in trial enrollment and subsequently clinical trial outcomes. 29 For example, because of aspects of the US health care system, insurance coverage has been found to be a significant predictor of US enrollment for oncology trials. 30 In addition, different countries around the globe have disparities in resource availability and variations in standards of care, which result in regional differences in practice. 31, 32 Trends in average age between continents (1990-2015). Data expressed as an average patient age calculated using the fixed-effects model. Each circle represents the sum of the sample sizes from each article that reported patient age published during each respective year.
Comparison of female enrollment in clinical trials between continents merits special consideration. Similar to our observation in PCI trials, a predominance of male participants in clinical trials has been similarly reported in heart failure 33 and in cardiovascular disease prevention publications. 34 Our global meta-analysis extends the finding that female enrollment in PCI trials is overall low. Trials from North America had the highest percentage of women enrolled due in part to the efforts of the National Heart, Lung and Blood institute. 35, 36 National Institutes of Health Revitalization Act (Public Law 103-43) required inclusion of female patients in clinical trials to "ensure that the trial is designed and carried out in a manner sufficient to provide for a valid analysis of whether the variables being studied in the trial affect women [and men] differently." 37 It is discouraging that we have not observed increased inclusion of women in the United States despite that 25 years have passed since the Revitalization Act. We feel that clinical trials should direct stronger effort toward gender balance during enrolment. This effort should be 2-fold-increasing access of trials to women and minorities and promoting research awareness among underrepresented populations. 38 Social ecology and genetic makeup of various trial populations around the globe add additional complexity to the extrapolation of results from PCI trials performed in different countries and continents. 1, 39, 40 Population ancestry and genetic risk have important implications on the development of cardiovascular disease. 40 Publication year in an important consideration when comparing different trials. For example, in a previous study of PCI outcomes, a gradual increase in patient age from 56 to 62 years in the 1994-2007 period was reported. However, no effect of PCI on death or myocardial infarction was observed when compared with medical therapy. 41 This underlines one of the most critical issues in comparing effectiveness of PCI over time because comparing outcomes between studies from different periods or continents which include heterogeneous patient populations may not yield accurate conclusions. In our mixed-effects logistic regression model, the publication year was not statistically significantly associated with percentage of baseline risk factors. Instead, it is the changing study demographics and inclusion of different patient population consisting of older and more obese patients that occurred during the study period and contributed to the observed differences. Treatment strategies for PCI continue to evolve over time on a background of constantly evolving medical therapy. It should be noted that large network meta-analyses that compare various PCI strategies frequently report results that are based on analysis of aggregate data and therefore may not fully control for heterogeneity in the patient populations included and this specific influence on their findings. 42 Therefore, significant caution is recommended when comparing trials due to differences in methodology and procedure characteristics.
The significant baseline differences in risk factors and heterogeneity we consistently observed have important implications for future research. Current published meta-analyses include a large number of clinical trials with both variable PCI procedure characteristics, methodology, duration of follow-up, and, as demonstrated in our study, significant baseline patient characteristics differences.
Globalization of clinical research has brought several advantages but also raises significant scientific questions. 1 One of the challenges of globalization is the difficulty in interpreting trial findings and generalizing them for particular populations. 43 Our data further confirm the great importance of performing trials addressing PCI questions to specific countries and continents. 44 The aforementioned factors along with our findings underline the limitations of applicability and generalizability for research performed outside the United States. 1, 44 Regulatory authorities have long recognized the variability and applicability of clinical trials performed in various global jurisdicitons. 45 Under the Code of Federal Regulations, Title 21, the Food and Drug Administration requires that international studies used for application of marketing approval comply with American standards and have applicability to the American population. 46 These policies have significant relevance to the cardiovascular realm. Multiple studies have demonstrated the impact of possible regional differences on outcomes in acute coronary syndrome. 47, 48 However, the strain from these additional regulations has resulted in increased cost of clinical trials and slowed the availability of new technologies for regulatory consideration. 49 
Implications
There are several potential implications for future research. We believe that meta-analyses could include additional control for baseline patient characteristics because it is likely that outcomes are affected by heterogeneity in study populations. Local research efforts should be encouraged as globalization of cardiology trials may not fully answer specific needs of certain population groups. Although randomization may even out the patient characteristics within a study, ongoing efforts should be made to attempt to recruit more representative and comparable populations in global mega-trials.
Study limitations
The clinical trials included in our systematic review were based on strict, prespecified selection criteria that may not represent the true baseline characteristics of PCI patients in a given region. The study was limited to any published available data and therefore does not include patient-level information that may have been collected but not published. We were also unable to take into consideration unpublished comorbidities, additional risk factors, and other moderators that may have contributed to the observed continental differences. The discrepancies we found between the random effects and the mixed effects with BMI models may be due to the low number of clinical trials that reported certain moderators, particularly BMI. In addition, the articles selected ranged from registries to clinical trials and contained heterogeneous patient selection criteria, disease severities, and interventions, among other reported factors, which gave us the opportunity to study a wide scope of the PCI literature but limited the interpretation of some of the analysis. Although underrepresentation of ethnic minorities in cardiovascular trials has been well described, we did not have sufficient data available to study ethnic makeup of global clinical trials. 50 Lastly, because of the larger number of publications in certain periods and countries, our study had biases toward studies published after 2000 and in countries with higher numbers of clinical trials (eg, the United States, Germany, France, and South Korea).
Conclusions
Major continental differences in HL, HTN, DM, and smoking prevalence and trends exist among patients with CAD enrolled in PCI trials. Women remain underrepresented in PCI clinical trials. Clinical trial results may not be generalizable to the patient population from another region. It is important to account for these differences when interpreting clinical trials from different regions of the globe. Globalization of cardiology research poses a new challenge to clinical cardiologists when interpreting data for daily practice and treating each individual patient.
